RE:RE:New Press Release - Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023As of the data cutoff date of July 28, 2022, 7 evaluable patients of 10 who were enrolled in the PDAC cohort of the GOBLET trial achieved a partial response, including 3 confirmed and 4 unconfirmed. Two more patients achieved stable disease for an ORR of 70% and a CBR of 90%, respectively.
These ORR data are nearly triple the average ORR which have been reported in historical control trials, suggesting that pelareorep synergizes with PD-L1 inhibitors and standard-of-care chemotherapy in patients with advanced/metastatic pancreatic ductal adenocarcinoma.
https://www.targetedonc.com/view/goblet-trial-s-pancreatic-cohort-displays-high-efficacy-with-pelareorep-atezolizumab
At SITC in October 2022 - As of the abstract's data cutoff date (July 28, 2022), seven of ten evaluable patients in GOBLET's PDAC cohort, which evaluates pelareorep in combination with Roche's anti-PDL1 checkpoint inhibitor atezolizumab and the chemotherapeutic agents gemcitabine and nab-paclitaxel, achieved a partial response (3 confirmed, 4 unconfirmed as of the cutoff date). An additional two patients achieved stable disease for an ORR and clinical benefit rate of 70% and 90%, respectively.
"The ORR reported in the SITC abstract is remarkably nearly triple the average ORR seen in historical control trials of gemcitabine plus nab-paclitaxel, which is only about 25%," said Dirk Arnold M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial.
As of October 2023 - Updated data from the study showed that 8 of 13 evaluable patients had a partial response (PR) and 3 had stable disease (SD) for an objective response rate (ORR) of 62% (53% confirmed with two scans) and a clinical benefit rate (CBR) of 85%. As of the data cut-off (January 19, 2023), the median duration of response was 6.0 months, the 6-month progression-free survival (PFS) rate was 72.9%, and the 6-month overall survival (OS) rate was 82.1%. T cell receptor sequencing (TCR-seq) showed an expansion of new and pre-existing T-cell clones.
Updated efficacy and TCR-seq results will be presented at ESMO
https://stockhouse.com/news/press-releases/2023/10/16/oncolytics-biotech-xae-to-present-two-posters-on-the-pelareorep-based-goblet